Literature DB >> 33749497

Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.

Jill Fulcher1, Philip Berardi2, Grace Christou1, Pierre J A Villeneuve1, Christopher Bredeson, Mitchell Sabloff1.   

Abstract

Entities:  

Year:  2021        PMID： 33749497     DOI： 10.1080/10428194.2021.1901097

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

Review 1.  Early T-Cell Precursor Acute Lymphoblastic Leukemia: Diagnosis, Updates in Molecular Pathogenesis, Management, and Novel Therapies.

Authors:  Chun-Fung Sin; Pui-Hei Marcus Man
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

2.  Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.

Authors:  Marco Cerrano; Massimiliano Bonifacio; Matteo Olivi; Antonio Curti; Michele Malagola; Michelina Dargenio; Anna Maria Scattolin; Cristina Papayannidis; Fabio Forghieri; Carmela Gurrieri; Ilaria Tanasi; Patrizia Zappasodi; Roberta La Starza; Nicola Stefano Fracchiolla; Patrizia Chiusolo; Luisa Giaccone; Maria Ilaria Del Principe; Fabio Giglio; Marzia Defina; Claudio Favre; Carmelo Rizzari; Barbara Castella; Giovanni Pizzolo; Felicetto Ferrara; Sabina Chiaretti; Robin Foà
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

3.  Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases.

Authors:  Ingolf Molle; Irma Petruskevicius; Peter Kamper; Francesco d'Amore
Journal:  Case Rep Hematol       Date:  2022-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.